RAPP News and Press, Rapport Therapeutics Inc.

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with ne...

2026-03-17 15:32:18 ET Rapport Therapeutics, Inc. (RAPP) Stifel 2026 Virtual CNS Forum March 17, 2026 9:30 AM EDT... Read the full article on Seeking Alpha For further details see: Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript

2026-03-10 07:29:00 ET More on Rapport Therapeutics Seeking Alpha’s Quant Rating on Rapport Therapeutics Historical earnings data for Rapport Therapeutics Financial information for Rapport Therapeutics Read the full article on Seeking Alpha For...

Blend Labs Inc. Class A (BLND) is expected to report $-0.02 for Q4 2025 United Natural Foods Inc. (UNFI) is expected to report $0.51 for Q2 2026 Consumer Portfolio Services Inc. (CPSS) is expected to report $0.23 for Q4 2025 Westrock Coffee Company (WEST) is expected to report $-0.1 f...

RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 RAP- 219 epilepsy portfolio expanded with new program in primary generalized tonic-cloni...

2026-03-09 18:38:21 ET Rapport Therapeutics, Inc. Common Stock (RAPP) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 6.47%. The average open to low on the day of earnings was -4.85%. Th...

2026-03-09 18:33:21 ET Rapport Therapeutics, Inc. Common Stock (RAPP) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in RAPP stock price following earnings has averaged ±0.87% , with a m...

2026-03-09 12:03:24 ET Kambiz Yazdi from BTIG issued a price target of $47.00 for RAPP on 2026-03-09 13:49:00. The adjusted price target was set to $47.00. At the time of the announcement, RAPP was trading at $29.965. The overall price target consensus is at $42.33 with ...

Partnership leverages Tenacia’s expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights to develop and commercialize RAP-219 in Greater China across indications, including foc...

2026-02-02 06:15:12 ET Wells Fargo analyst issues OVERWEIGHT recommendation for RAPP on February 2, 2026 10:58AM ET. RAPP was trading at $26.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy reco...